SPOTLIGHT: IDM Pharma outlines plans for Junovan

San Diego-based IDM Pharma confirmed plans to submit an NDA for Junovan as a therapy for osteosarcoma following a pre-NDA meeting with the FDA. Osteosarcoma is a bone cancer that occurs predominantly in adolescents and young adults. Release

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.